Embedded Files
Asymmetric Antibody withEnhanced Target Cell Clearance (JP)
pH-sensitive Fc variants (JP)
A Novel Antibody Specificfor CD55 and Use Thereof (JP)
Antibody Fc Variants forImproving Blood Half-Life ( JP)
Antibody Fc Variants forImproving Blood Half-Life (US)
Endothelin Receptor Type A Activity Regulating Antibody
PD-L1 Variants with EnhanceBinding Affinity to PD-1
A Novel Antibody Specificfor CD55 and Use Thereof
Human IgG1 Fc variant with improvedpH-dependent FcRn bindingand Fc gamma receptor IIa binding selectivity
Antibodies with Improved Binding Affintiy to Fc Alpha ReceptorTargeting SARS-CoV-2
Fc Variatns with Modulated Effector Functions and Prolonged Serum Half-Lives
Asymmetric Antibody withEnhanced Target Cell Clearance
Antibody Fc variants optimizedfor pH-selective FcRn binding
Antibody Fc variants with Enhanced pH-dependent FcRn binding
pH-sensitive Fc variants
Human AntibodiesTargeting SARS-CoV-2
Flavin mononucleotide binding protein variants derived from Pseudomonas putida with enhanced fluorescence intensity
Glycosylated PD-1 mutant for increased PD-L1 binding force
PD-1 mutant with increased PD-L1 binding force
Aglycosylated PD-1 variantswith enhanced binding to PD-L1
Anti-GPR87 antibody
Antibody Fc variants for increased blood half-life
Endothelin receptor type A activity regulating antibody (JP)
Antibody with enhanced binding to endothelin receptor type A (JP)
Flavin mononucleotide binding protein variants with improved fluorescent strength (JP)
Fc gamma receptor mutants (US)
Antibody Fc variants for improved serum half-life (JP)
Antibody Fc variants for improved blood half-life (CA)
pH-Sensitive Fc variants
Aglycosylated antibody Fc region for treating cancer (GB)
Fc gamma receptor mutants (EU)
Antibody Fc variants for increased blood half-life (US)
Aglycosylated antibody Fc region for treating cancer (US)
Fc gamma receptor mutants (JP)
pH sensitive Fc variants
Aglycosylated antibody Fc region for treating cancer
PD-1 mutant with increased PD-L1 binding force (JP)
Antibody with enhanced binding toendothelin receptor type A
Antibodies regulating functions of an endothelin receptor type A
PD-1 variant having improved binding to PD-L1 (AU)
Antibody Fc variants for improving blood half-life (AU)
Fc gamma receptor mutants (AU)
PD-L1 variants with enhanced PD-1 binding affinity
Flavin mononucleotide binding protein variants with enhanced fluorescence intensity
Aglycosylated PD-1 variants with enhanced PD-L1 binding affinity
Multimeric protein display system using cell membrane fluidity
Human antibodies regulating functionsof a G-protein coupled receptor
Fc gamma receptor variant, MG2A45
Fc gamma receptor variant MG2A28
Fc gamma receptor variant SH2A40
An antibody Fc variant for enhancing ADCC activity
Antibody Fc variants for prolonged serum half-life
Antibody Fc variants for prolonged serum half-life
Antibody Fc variants for prolonged serum half-life
Aglycosylated antibody Fc region exhibiting enhanced binding specificity to an Fcγ receptor
Aglycosylated antibody Fc region for treating cancer
Antibody Fc region comprising a new mutation
Fc Gamma Receptor Variant, MG2A28
Fc Gamma Receptor Variant, MG2A28.1
Fc Gamma Receptor Variant, MG2A45.1
Fc Gamma Receptor Variant, MG2B45.1
Amphipathic polymer for DNA amplification with high sensitivity and methods for nucleic acid amplification using the same
Flavin-based fluorescent protein variant
Antibody Fc variants for extended serum half-life
Antibody Fc variants for prolonged serum persistence
Page updated
Google Sites
Report abuse